To assess changes in medication use after a diagnosis of dementia in individuals with type 2 diabetes mellitus. DESIGN: Difference-in-differences analysis of changes in the number of dispensed chronic medications between individuals with and without newly diagnosed dementia. SETTING: Integrated healthcare delivery system, Kaiser Permanente Northern California. PARTICIPANTS: Individuals aged 50 and older without prevalent dementia with type 2 diabetes mellitus enrolled in a baseline survey. During 5 years of follow-up, 193 individuals with a new diagnosis of dementia were identified, and risk-set sampling was used to randomly select five reference subjects per case matched on 5-year age categories and sex (965 matched participants), resulting in an analytical sample of 1,158. MEASUREMENTS: The exposure was new diagnosis of dementia. The primary outcome was change in number of current chronic medications (total, cardiovascular (blood pressure and lipid control), diabetes mellitus) at three times: 1 year before index date (preindex date), date of diagnosis of dementia or matched reference date (index date), and up to 1 year after index date or end of followup if censored before 1 year (postindex date). RESULTS: After adjustment, the number of chronic medications and the subset of cardiovascular medications declined after a dementia diagnosis in the overall cohort and in age-, sex-, and time-matched reference individuals, but the decline was significantly greater in the group with dementia (0.71 medications fewer than the reference group, P = .02). The number of diabetes mellitus medications declined in both groups, but the declines were not statistically different (0.18 medications fewer than the reference group, P = .008). CONCLUSIONS: Use of cardiometabolic medications fell after a diagnosis of dementia, as recommended in national guidelines. J Am Geriatr Soc 65:77-82, 2017.
ny chronic condition care management strategy must weigh the risks and benefits of treatment, but the optimal balance is dynamic and may shift with function, wellbeing, and health status. The goal of chronic disease management is typically to prevent long-term complications of a disease, but as life expectancy shortens, the opportunity for people to realize the benefits of long-term use of medications diminishes. At the same time, polypharmacy and the associated risks of adverse events (e.g., falls 1 ) may increase with age. For the oldest and sickest individuals, clinicians may modify chronic condition care management strategies by discontinuing medications to reduce the risks of polypharmacy and deemphasize prevention of long-term complications. [2] [3] [4] An excellent example of a clinical scenario in which chronic disease management may require individualization is an older adult with diabetes mellitus and incident dementia. Observational studies and clinical trials have demonstrated that, for many older adults with diabetes mellitus, the harms of aggressive glycemic control in the short term will outweigh the long-term benefits of preventing microvascular and cardiovascular complications. 1, 2, [5] [6] [7] Polypharmacy becomes a particular concern for older adults with incident dementia and comorbid diabetes mellitus. Administering medications may be a significant burden on caregivers, and the diagnosis of dementia often necessitates a change in strategy, with a reduction in the number of diabetes mellitus or cardiovascular medications used to prevent long-term complications. For more than a decade, diabetes mellitus care guidelines for older adults have advised de-intensification of treatment for individuals with dementia, based on the changing balance of risks and benefits. [8] [9] [10] [11] Despite these guidelines, little is known about changes in medication use after a diagnosis of dementia in realworld clinical practice. Changes in the number of medications dispensed for glycemic, blood pressure (BP), and lipid control before and after an incident diagnosis of dementia were evaluated in a large cohort of older adults with diabetes mellitus to determine whether medication simplification occurred as recommended.
METHODS

Study Setting
The study design was based on a prospective follow-up of a large, multiethnic cohort of fully insured older adults with diabetes mellitus (Diabetes and Aging Study). All study subjects received care from a large, nonprofit, integrated healthcare delivery system: Kaiser Permanente Northern California (KPNC), 6 which provides care to more than 3 million health plan members (25-30% of the population of the San Francisco Bay and Sacramento metropolitan region of northern California). The membership is ethnically and socioeconomically similar to the overall population living in the region. 12 KPNC provides care to a population through employer-based plans, Medicare, Medicaid, and the new health insurance exchange. KPNC is not a fee-for-service or claims-based healthcare delivery system but provides prepaid care that integrates all outpatient, inpatient, laboratory, and pharmacy services. KPNC uses a state-of-the-art electronic medical record that comprehensively captures data on all health plan members, including processes of care, inpatient and outpatient usage, medical diagnoses, procedures, and costs. The health plan maintains a closed pharmacy system in which pharmacy benefits are available only at health plan pharmacies, with comprehensive capture of pharmacy usage for the 96% of members with pharmacy benefits, as well as identification of members who transfer their prescriptions to out-of-plan pharmacies. 13, 14 This cohort has been described in detail previously. 15 All subjects were identified in the KPNC Diabetes Registry using health plan data and a validated algorithm. 16 The registry was first established in 1993 and is updated annually from automated databases of pharmacy data, laboratory data, hospitalization records, and outpatient diagnoses using standardized criteria. 15 It has an estimated sensitivity of 99% based on chart review validation. 15 These data have been used previously to characterize the natural history of diabetic complications and mortality in a variety of subpopulations in numerous epidemiological and health services investigations. 14, 15, [17] [18] [19] 
Sample Selection
Several of the variables required for this analysis were not contained in electronic medical record data (e.g., education), so analysis was focused on a cohort of 20,188 individuals with diabetes mellitus who responded to the Diabetes Study of Northern California survey, a 184-item questionnaire administered from May 2005 to January 2007. 20 One hundred nine individuals who had unclear dementia status or evidence of prevalent dementia (previous dementia diagnoses based on codes listed below) and 978 with type 1 diabetes mellitus were excluded. 21 During a 5-year follow-up starting with each subject's survey date, incident cases of clinically recognized dementia were identified using a validated method 22 using outpatient and inpatient reports of one or more International Classification of Diseases, Ninth Revision, Clinical Modification, diagnostic codes of uncomplicated senile dementia (290.0), Alzheimer's disease (331.01), vascular dementia (290.4), or dementia not otherwise specified (290.1). The date of the initial diagnosis of dementia was used as the index date. In this analytical cohort, 193 individuals with an incident diagnosis of dementia were identified (after 47 who lacked continuous prescription medication benefits as part of their insurance coverage were excluded). Risk-set sampling was then used to randomly select 965 reference participants by selecting five cohort members with no dementia diagnosis per each participant with incident dementia, group-matched on 5-year age categories and sex, all of whom had continuous prescription medication benefits. The index date (month, year) for each reference participant was the dementia diagnosis date of the matched exposed participant. This resulted in a total analytical sample of 1,158.
Outcome
The primary outcome was change in number of current chronic medications at three points: 1 year before index date (preindex date), date of diagnosis of dementia or matched reference date (index date), and up to 1 year after index date or end of follow-up if censored before 1 year (postindex date). The same algorithm was used for counting medications as in previous work in this population; 23 for each point in time (preindex, index, postindex), every medication dispensed with a 30-day supply or more within the prior 6 months based on outpatient pharmacy dispensing records was identified.
All medications were categorized according to indication: dementia, cardiovascular (lipid-lowering, antihypertensive), diabetes mellitus, or other. A clinician researcher (US) reviewed the list of prescribed medications to categorize them according to class using internal classification data. If a medication contained two different active ingredients, even if they were in different classes, each ingredient was assigned to its appropriate type, and each was counted as one medication in the total medication count for up to three active ingredients per prescribed medication. The categories were necessary because it was hypothesized that clinicians might add medications to control dementia symptoms while discontinuing diabetes mellitus or cardiovascular medications, and a total count would mask these differences. The "other" category included antihistamines, aspirin, calcium, and magnesium, but in general medications that are not typically indicated for long-term use were excluded. Because prescription medication dispensing data were used, over-the-counter medication use was not captured. For participants using multiple medications from the same general class of medications (e.g., diuretics), each distinct medication within the class was counted as an individual drug. Diabetes mellitus medications included insulin and oral hypoglycemic medications; cardiovascular medications included BP and cholesterol management medications; and dementia medications included medications such as cholinesterase inhibitors (donepezil, galantamine, rivastigmine, tacrine), memantine, vitamin E, antipsychotics to treat behavioral disturbances associated with dementia, and antidepressants (because depression is common in individuals with dementia, and some people use these to treat behavioral disturbances as well).
Covariates
A directed acyclic graph (DAG) depicting hypothesized causal relationships and temporal ordering between the exposure (diagnosis of dementia), outcome of interest (number of medications for chronic conditions), and related variables was constructed. Established DAG rules were used to determine the subset of covariates needed to estimate the unbiased direct effect of incident dementia diagnosis on medication count and risk factor control. 24, 25 The final adjusted models included self-reported education, race, and social support and information from clinical records on duration of diabetes mellitus, glycosylated hemoglobin, BP, low-density lipoprotein cholesterol, body mass index, number of outpatient visits in the 12 months before the index date, number of hospitalizations in the 12 months before the index date, Medical Outcomes Study 8-item Short-Form Survey physical function score, 26 and Charlson Comorbidity Index score in the calendar year of the preindex date. [27] [28] [29] Because participants were matched on age and sex to identify the reference population, these characteristics were not adjusted for.
Analysis
A difference-in-differences (DID) analytical framework based on a pre-post design with a reference group was used. [30] [31] [32] [33] The reference group provides an estimate of the expected background change in the outcome, which is then subtracted from the change observed in the incident dementia group to estimate a net causal effect. This conservative approach yields a DID estimate for the change in number of medications or risk factor control associated with incident dementia diagnosis (the exposure) in addition to the expected change in medication count or risk factor control due to factors such as secular trends, aging, and regression to the mean.
For initial, unadjusted analyses of medication count outcomes (total and according to medication category), differences in medication counts at each time point were graphically examined (Figure 1) , and paired t-tests between the first (i.e., preindex) and last (i.e., postindex) time point were used to examine whether differences were significant. For adjusted analyses, the DID estimate was calculated using least-squares regression models, also examining the change between the first and last time points. The models adjusted for preindex number of medications and all covariates listed above ( Table 2 ). Very little clustering of participants according to physician was found in the study sample, and so physician clustering was not accounted for in the adjusted models (data not shown).
Data preparation was performed using SAS version 9.3 (SAS Institute, Inc., Cary, NC). All analyses were performed in Stata version 12, including the diff package with Figure 1 . Number of prescribed preindex medications, postindex medications, and medications at time of dementia diagnosis. , number of medications for participants with dementia. , number of medications for participants without dementia. bootstrapped confidence intervals for the DID models (Stata Corp., College Station, TX).
RESULTS
The final cohort of 1,158 participants included 193 with clinically recognized incident dementia. Because they were matched on age and sex, these variables did not differ between cases and reference participants; 47% were female, and 75% were aged 70 and older (Table 1) . Overall, 93% of participants had diabetes mellitus for 5 years or longer, 50% had a high school diploma or less, and 76% were nonwhite (25% Asian, 19% black, 17% Hispanic). The only significant differences between the groups were that participants with incident dementia were more likely to have had diabetes for 20 years or longer (33% vs 21%, P = .001) and a higher mean Charlson score (3.4 vs 2.8, P = .001) than reference participants.
Participants who developed clinically recognized dementia used slightly more preindex chronic medications (6.8) than reference participants (6.3) (P = .05, Figure 1 ). In the postindex period, the number of medications decreased in both groups, but this decrease was greater in participants with dementia (1.3 fewer) than in reference participants (0.5 fewer) (P = .004). As expected, use of dementia medications increased in participants diagnosed with dementia (data not shown). Mean number of diabetes mellitus or cardiovascular medications did not change for reference participants, but numbers of both medication types decreased for those with dementia. In the preindex period, 983 (85%) were taking one or more diabetes medications, and 1,098 (95%) were taking one or more cardiovascular medications. In the postindex period, 938 (81%) were taking one or more diabetes mellitus medications, and 1,063 (92%) were taking one or more cardiovascular medications. There were no differences in the proportions using these medications according to dementia diagnosis (P > .05 for all). After adjusting for education; race; social support; duration of diabetes mellitus; preindex glycosylated hemoglobin, BP, low-density lipoprotein cholesterol, and body mass index; number of outpatient visits in the 12 months before the index date; number of hospitalizations in the 12 months before the index date; preindex comorbidity score; and preindex Medical Outcomes Study 8-item ShortForm Survey score, a significantly greater decline was found in number of overall and cardiovascular medications in participants with dementia than in reference participants. The number of diabetes mellitus medications declined very slightly, but significantly between the groups (Table 2) .
DISCUSSION
This observational study of older adults with diabetes mellitus found that the overall number of medications, and of diabetes mellitus and cardiovascular medications in particular, declined after a dementia diagnosis, and the difference was greater than in age-, sex-, and time-matched reference participants. These results suggest that providers in this integrated healthcare delivery system are de-intensifying use of long-term diabetes mellitus and cardiovascular medications after a dementia diagnosis, as recommended in current care guidelines.
Prior studies of diabetes management in older populations have found continued aggressive glycemic treatment, 34, 35 despite clear evidence that harms outweigh benefits. 36, 37 It has been suggested that clinicians do not individualize diabetes mellitus treatments sufficiently, leading to overtreatment in elderly adults. 38 Conversely, there is evidence that there is underprescribing in managing elderly adults with comorbidities. 39 Optimizing prescribing for elderly adults requires addressing over-and underprescribing. Small decreases were seen in the number of diabetes mellitus medications in participants with dementia compared to the reference group. It is possible that clinicians are more willing to de-intensify diabetes mellitus treatment in individuals with diagnosed dementia than in elderly adults more generally. A growing recognition of the harms of overtreatment may also have influenced these findings. 40 This study has several strengths. It examined a wellcharacterized cohort with relatively uniform access to care over time with robust clinical and survey data capture. The DID approach accounts for changes in medication prescribing practices over time and other secular trends while controlling for confounding by individual characteristics. There are also limitations. Physician diagnosis of dementia was used to identify incident cases of dementia, which may underascertain dementia and therefore introduce a conservative bias. Moreover, it cannot be verified that medication discontinuation occurred because of dementia diagnosis; it may have been due to resultant frailty, adverse effects, or participant preference. In this observational study, whether the dementia diagnosis led directly to a change in care management strategy with a reduction in prescribed medication use cannot be ascertained, although selection of a closely matched reference population and adjusted analysis should have provided good comparability of the two groups. The statistical power in this very diverse cohort was inadequate to examine differences according to race and ethnicity. Finally, this analysis included individuals cared for in an integrated health system; these results may not generalize to other types of healthcare delivery systems.
Overall, these results suggest that healthcare providers are simplifying medication regimens for individuals with diabetes mellitus who develop dementia. This may be a deliberate result of decision-making about medications. This encouraging finding deserves additional research regarding the individual-, provider-, and system-level mechanisms that drive recommended changes in medication use in older adults with dementia and other chronic conditions. More research is also needed to determine the long-term consequences of de-intensification versus maintenance versus intensification of diabetes mellitus care to solidify the evidence-base for care recommendations for the sickest and most medically complex individuals.
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